Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers
ABSTRACT: Zopiclone is a hypnotic short-acting agent used in the treatment of primary insomnia. The aim of this study was to compare the Bioequivalence of two formulations of Zopiclone available in the Colombian market: Zopiclone 7.5 mg commercialized as Zopiclone MK® and Zopicloteg TG® (Test produc...
- Autores:
-
Ruiz Correa, Adriana María
Cuesta González, Fanny
Castaño Arias, Paula Andrea
Correa Cano, Omar de Jesús
Gómez Álvarez, Karina
Jaramillo Montoya, Maria Elena
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2015
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/35893
- Acceso en línea:
- https://hdl.handle.net/10495/35893
https://www.longdom.org/bioequivalence-bioavailability.html
- Palabra clave:
- Disponibilidad Biológica
Biological Availability
Equivalencia Terapéutica
Therapeutic Equivalency
Cromatografía Líquida de Alta Presión
Chromatography, High Pressure Liquid
Eszopiclona
Eszopiclone
Farmacocinética
Pharmacokinetics
- Rights
- openAccess
- License
- https://creativecommons.org/licenses/by/4.0/
| id |
UDEA2_8d2a6b48c667f0ca68ff079b0809a251 |
|---|---|
| oai_identifier_str |
oai:bibliotecadigital.udea.edu.co:10495/35893 |
| network_acronym_str |
UDEA2 |
| network_name_str |
Repositorio UdeA |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers |
| title |
Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers |
| spellingShingle |
Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers Disponibilidad Biológica Biological Availability Equivalencia Terapéutica Therapeutic Equivalency Cromatografía Líquida de Alta Presión Chromatography, High Pressure Liquid Eszopiclona Eszopiclone Farmacocinética Pharmacokinetics |
| title_short |
Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers |
| title_full |
Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers |
| title_fullStr |
Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers |
| title_full_unstemmed |
Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers |
| title_sort |
Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers |
| dc.creator.fl_str_mv |
Ruiz Correa, Adriana María Cuesta González, Fanny Castaño Arias, Paula Andrea Correa Cano, Omar de Jesús Gómez Álvarez, Karina Jaramillo Montoya, Maria Elena |
| dc.contributor.author.none.fl_str_mv |
Ruiz Correa, Adriana María Cuesta González, Fanny Castaño Arias, Paula Andrea Correa Cano, Omar de Jesús Gómez Álvarez, Karina Jaramillo Montoya, Maria Elena |
| dc.contributor.researchgroup.spa.fl_str_mv |
Grupo de Estudio e Investigaciones Biofarmacéuticas |
| dc.subject.decs.none.fl_str_mv |
Disponibilidad Biológica Biological Availability Equivalencia Terapéutica Therapeutic Equivalency Cromatografía Líquida de Alta Presión Chromatography, High Pressure Liquid Eszopiclona Eszopiclone Farmacocinética Pharmacokinetics |
| topic |
Disponibilidad Biológica Biological Availability Equivalencia Terapéutica Therapeutic Equivalency Cromatografía Líquida de Alta Presión Chromatography, High Pressure Liquid Eszopiclona Eszopiclone Farmacocinética Pharmacokinetics |
| description |
ABSTRACT: Zopiclone is a hypnotic short-acting agent used in the treatment of primary insomnia. The aim of this study was to compare the Bioequivalence of two formulations of Zopiclone available in the Colombian market: Zopiclone 7.5 mg commercialized as Zopiclone MK® and Zopicloteg TG® (Test product) manufactured by Tecnoquímicas S.A (Cali, Col.) and Imovane® (Reference product) from Sanofi-Aventis Farmacéutica Ltda (Brasil). With this purpose, a single dose, randomized, crossover, with two periods, two sequences and a washout period of one week study was developed. Blood samples were drawn from 0 to 24 hours following the drug administration. Zopiclone plasma levels were determined by HPLC method, validated under the FDA parameters. The 90% confidence intervals for the ratios of the ln AUC0-∞ and ln Cmax means between the Test and Reference product were constructed. The 80/125 rule was used as bioequivalence criterion. The study was conducted in 26 healthy volunteers. The estimated pharmacokinetic parameters for Zopiclone, either for the Test product or Reference product were Cmax 72.815 ± 20.54 ng/mL, 74.315 ± 18.04 ng/mL; AUC0-t 467.297 ± 92.21 ng.h/mL, 460.996 ± 115.81 ng.h/mL, and AUC0-∞ 560.298 ± 118.58 ng.h/ mL, 543.549 ± 136.97 ng.h/mL, respectively. The 90% confidence intervals for the ratio between the averages of ln-transformed data of AUC0-∞ and Cmax were 97.38% - 110.59% and 89.97% - 104.84%, respectively. Conclusion: In the present study of single dose, the Test product, Zopiclone 7.5 mg, meets the Bioequivalence criterion regarding the rate and extent of absorption. |
| publishDate |
2015 |
| dc.date.issued.none.fl_str_mv |
2015 |
| dc.date.accessioned.none.fl_str_mv |
2023-07-12T16:49:09Z |
| dc.date.available.none.fl_str_mv |
2023-07-12T16:49:09Z |
| dc.type.spa.fl_str_mv |
Artículo de investigación |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.redcol.spa.fl_str_mv |
https://purl.org/redcol/resource_type/ART |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| status_str |
publishedVersion |
| dc.identifier.citation.spa.fl_str_mv |
Ruiz A, Cuesta F, Castaño P, Correa O, Gómez K (2015) Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers. J Bioequiv Availab 7: 233-238. doi:10.4172/jbb.1000246 |
| dc.identifier.issn.none.fl_str_mv |
0975-0851 |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/10495/35893 |
| dc.identifier.doi.none.fl_str_mv |
10.4172/jbb.1000246 |
| dc.identifier.url.spa.fl_str_mv |
https://www.longdom.org/bioequivalence-bioavailability.html |
| identifier_str_mv |
Ruiz A, Cuesta F, Castaño P, Correa O, Gómez K (2015) Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers. J Bioequiv Availab 7: 233-238. doi:10.4172/jbb.1000246 0975-0851 10.4172/jbb.1000246 |
| url |
https://hdl.handle.net/10495/35893 https://www.longdom.org/bioequivalence-bioavailability.html |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartofjournalabbrev.spa.fl_str_mv |
J. Bioequivalence. Bioavailab. |
| dc.relation.citationendpage.spa.fl_str_mv |
238 |
| dc.relation.citationissue.spa.fl_str_mv |
5 |
| dc.relation.citationstartpage.spa.fl_str_mv |
233 |
| dc.relation.citationvolume.spa.fl_str_mv |
7 |
| dc.relation.ispartofjournal.spa.fl_str_mv |
Journal of Bioequivalence and Bioavailability |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by/2.5/co/ |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/2.5/co/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.extent.spa.fl_str_mv |
6 |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
OMICS Publishing Group |
| dc.publisher.place.spa.fl_str_mv |
Hyderabad, India |
| institution |
Universidad de Antioquia |
| bitstream.url.fl_str_mv |
https://bibliotecadigital.udea.edu.co/bitstreams/9fbc9b0b-f865-4e98-804f-db4ce7f0d968/download https://bibliotecadigital.udea.edu.co/bitstreams/8c78dc7b-943e-4777-91b9-4beefcda55cc/download https://bibliotecadigital.udea.edu.co/bitstreams/97949ca5-a022-45e9-b2e6-a543a3dd2bed/download https://bibliotecadigital.udea.edu.co/bitstreams/15fdee5b-2c0d-45a1-95bb-c0d82ea9aa9a/download https://bibliotecadigital.udea.edu.co/bitstreams/25b8b6ba-25a2-4571-a71d-3bc0d68f1fa4/download |
| bitstream.checksum.fl_str_mv |
1646d1f6b96dbbbc38035efc9239ac9c 8a4605be74aa9ea9d79846c1fba20a33 28e74ac17812dc6e97a90e26000190fc 6da29ea006021aa57bc54152a86c011e c2363943268bbddefa852d0450bbbc44 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional de la Universidad de Antioquia |
| repository.mail.fl_str_mv |
aplicacionbibliotecadigitalbiblioteca@udea.edu.co |
| _version_ |
1851052302780071936 |
| spelling |
Ruiz Correa, Adriana MaríaCuesta González, FannyCastaño Arias, Paula AndreaCorrea Cano, Omar de JesúsGómez Álvarez, KarinaJaramillo Montoya, Maria ElenaGrupo de Estudio e Investigaciones Biofarmacéuticas2023-07-12T16:49:09Z2023-07-12T16:49:09Z2015Ruiz A, Cuesta F, Castaño P, Correa O, Gómez K (2015) Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian Volunteers. J Bioequiv Availab 7: 233-238. doi:10.4172/jbb.10002460975-0851https://hdl.handle.net/10495/3589310.4172/jbb.1000246https://www.longdom.org/bioequivalence-bioavailability.htmlABSTRACT: Zopiclone is a hypnotic short-acting agent used in the treatment of primary insomnia. The aim of this study was to compare the Bioequivalence of two formulations of Zopiclone available in the Colombian market: Zopiclone 7.5 mg commercialized as Zopiclone MK® and Zopicloteg TG® (Test product) manufactured by Tecnoquímicas S.A (Cali, Col.) and Imovane® (Reference product) from Sanofi-Aventis Farmacéutica Ltda (Brasil). With this purpose, a single dose, randomized, crossover, with two periods, two sequences and a washout period of one week study was developed. Blood samples were drawn from 0 to 24 hours following the drug administration. Zopiclone plasma levels were determined by HPLC method, validated under the FDA parameters. The 90% confidence intervals for the ratios of the ln AUC0-∞ and ln Cmax means between the Test and Reference product were constructed. The 80/125 rule was used as bioequivalence criterion. The study was conducted in 26 healthy volunteers. The estimated pharmacokinetic parameters for Zopiclone, either for the Test product or Reference product were Cmax 72.815 ± 20.54 ng/mL, 74.315 ± 18.04 ng/mL; AUC0-t 467.297 ± 92.21 ng.h/mL, 460.996 ± 115.81 ng.h/mL, and AUC0-∞ 560.298 ± 118.58 ng.h/ mL, 543.549 ± 136.97 ng.h/mL, respectively. The 90% confidence intervals for the ratio between the averages of ln-transformed data of AUC0-∞ and Cmax were 97.38% - 110.59% and 89.97% - 104.84%, respectively. Conclusion: In the present study of single dose, the Test product, Zopiclone 7.5 mg, meets the Bioequivalence criterion regarding the rate and extent of absorption.COL00494536application/pdfengOMICS Publishing GroupHyderabad, Indiahttps://creativecommons.org/licenses/by/4.0/http://creativecommons.org/licenses/by/2.5/co/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2Bioavailability Comparison of Two Zopiclone Formulations in Healthy Colombian VolunteersArtículo de investigaciónhttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Disponibilidad BiológicaBiological AvailabilityEquivalencia TerapéuticaTherapeutic EquivalencyCromatografía Líquida de Alta PresiónChromatography, High Pressure LiquidEszopiclonaEszopicloneFarmacocinéticaPharmacokineticsJ. Bioequivalence. Bioavailab.23852337Journal of Bioequivalence and BioavailabilityPublicationCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8927https://bibliotecadigital.udea.edu.co/bitstreams/9fbc9b0b-f865-4e98-804f-db4ce7f0d968/download1646d1f6b96dbbbc38035efc9239ac9cMD52falseAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/8c78dc7b-943e-4777-91b9-4beefcda55cc/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADORIGINALRuizAdriana_2015_Bioavailability_Comparison_Two_Zopiclone.pdfRuizAdriana_2015_Bioavailability_Comparison_Two_Zopiclone.pdfArtículo de investigaciónapplication/pdf1000244https://bibliotecadigital.udea.edu.co/bitstreams/97949ca5-a022-45e9-b2e6-a543a3dd2bed/download28e74ac17812dc6e97a90e26000190fcMD51trueAnonymousREADTEXTRuizAdriana_2015_Bioavailability_Comparison_Two_Zopiclone.pdf.txtRuizAdriana_2015_Bioavailability_Comparison_Two_Zopiclone.pdf.txtExtracted texttext/plain36185https://bibliotecadigital.udea.edu.co/bitstreams/15fdee5b-2c0d-45a1-95bb-c0d82ea9aa9a/download6da29ea006021aa57bc54152a86c011eMD54falseAnonymousREADTHUMBNAILRuizAdriana_2015_Bioavailability_Comparison_Two_Zopiclone.pdf.jpgRuizAdriana_2015_Bioavailability_Comparison_Two_Zopiclone.pdf.jpgGenerated Thumbnailimage/jpeg16965https://bibliotecadigital.udea.edu.co/bitstreams/25b8b6ba-25a2-4571-a71d-3bc0d68f1fa4/downloadc2363943268bbddefa852d0450bbbc44MD55falseAnonymousREAD10495/35893oai:bibliotecadigital.udea.edu.co:10495/358932025-03-26 20:13:20.298https://creativecommons.org/licenses/by/4.0/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.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 |
